Pembrolizumab-Associated Bullous Pemphigoid with Laryngeal Involvement.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 39225134.
- Also identified by DOI 10.1002/lary.31743 and PMC identifier 11635147.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Pembrolizumab is a monoclonal antibody with increasing use in many malignancies. We describe a case of pembrolizumab-associated bullous pemphigoid (BP) with laryngeal involvement in a 69-year-old male patient. Diagnosis was made after 2 months of symptoms via biopsy of concurrent, easily accessible cutaneous lesions. Pembrolizumab was discontinued and the patient was started on steroids and dupilumab with ultimate resolution of his cutaneous and laryngeal lesions while on immunosuppression. This case report describes the third case of pembrolizumab-associated laryngeal pemphigoid to increase awareness of this rare immune-related adverse effect. Laryngoscope, 135:243-246, 2025.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Pemphigoid, Bullous